| Initial cohort | Validation cohort | P value | ||||
---|---|---|---|---|---|---|---|
Characteristics | Training dataset (n = 52) | Validation dataset (n = 17) | Testing dataset (n = 17) | P value | Total (n = 86) | (n = 30) |  |
Age(y) | 61 ± 10 | 58 ± 11 | 59 ± 11 | 0.737 | 60 ± 11 | 59 ± 10 | 0.592 |
Gender [N (%)] | Â | Â | Â | 0.398 | Â | Â | 0.071 |
  Male | 21(40.38%) | 10 (58.82%) | 7 (41.18%) |  | 38 (44.19%) | 19 (63.33%) |  |
  Female | 31(59.62%) | 7 (41.18%) | 10 (58.82%) |  | 48 (55.81%) | 11 (36.67%) |  |
Location of the primary tumor [N (%)] | Â | Â | Â | 0.992 | Â | Â | 0.135 |
  Rectal cancer | 10 (19.23%) | 4 (23.53%) | 2 (11.76%) |  | 16 (18.60%) | 8 (26.67%) |  |
  Colon cancer | 16 (30.77%) | 5 (29.41%) | 6 (35.29%) |  | 27 (31.40%) | 7 (23.33%) |  |
  Breast cancer | 8 (15.38%) | 2 (11.76%) | 2 (11.76%) |  | 12 (13.95%) | 3 (10.00%) |  |
  Renal cancer | 4 (7.70%) | 1 (5.88%) | 1 (5.88%) |  | 6 (6.98%) | 5 (16.67%) |  |
  Prostate cancer | 3 (5.77%) | 0 (0.00%) | 2 (11.76%) |  | 5 (5.81%) | 0 (0.00%) |  |
  Small bowel cancer | 3 (5.77%) | 1 (5.88%) | 1 (5.88%) |  | 5 (5.81%) | 3 (10.00%) |  |
  Lung cancer | 2 (3.85%) | 2 (11.76%) | 1 (5.88%) |  | 5 (5.81%) | 4 (13.33%) |  |
  Others | 6 (11.54%) | 2 (11.76%) | 2 (11.76%) |  | 10 (11.63%) | 0 (0.00%) |  |
Number of target lesions [N (%)] | Â | Â | Â | 0.345 | Â | Â | 0.006 |
  1 | 14 (26.92%) | 2 (11.76%) | 6 (35.29%) |  | 22 (25.58%) | 8 (9.30%) |  |
  2 | 7 (13.46%) | 4 (23.53%) | 1 (5.88%) |  | 12 (13.95%) | 4 (4.65%) |  |
  3 | 4 (7.69%) | 2 (11.76%) | 0 (0.00%) |  | 6 (6.98%) | 10 (11.63%) |  |
  4 | 6 (11.54%) | 3 (17.65%) | 5 (29.41%) |  | 14 (16.28%) | 2 (2.33%) |  |
   ≥ 5 | 21 (40.38%) | 6 (35.29%) | 5 (29.41%) |  | 32 (37.21%) | 6 (6.98%) |  |
Baseline lesion size (cm) | 6.6 | 7.0 | 5.6 | 0.813 | 6.5 | 4.7 | 0.126 |
Baseline lesion volume (cm3) | 308.51 | 214.70 | 55.83 | 0.801 | 240.02 | 61.37 | 0.615 |
ADC value of baseline lesion (mm2/s) | 1.1 | 1.2 | 1.2 | 0.903 | 1.1 | 1.0 | 0.090 |